Allegheny Health Network Ongoing Efforts to Ensure that Frontline Hospital Caregivers Are Protected to Help Prevent Exposure to COVID-19 and Other Infectious Diseases

June 24, 2020

Allegheny Health Network (AHN) reported today they have partnered with Pittsburgh-based manufacturer Magee Plastics Company to design and equip caregiver teams with protective barrier enclosures that reduce clinical exposure to coughed droplets and aerosols produced during medical procedures on patients.

Allegheny Health Network notes the collaboration between the two organizations is supported by a $150,000 grant from the Richard King Mellon Foundation.

The protective barrier enclosure is produced by Magee Plastics and consists of a transparent plastic cube designed to cover a patient’s head while they are in a hospital bed. Used as a physical barrier, the cube incorporates one or more ports through which the health care provider’s hands are passed to perform medical procedures related to airway management such as intubation, extubation, and suctioning of airways, and any aerosol-generating procedures such as nebulizer treatments and manipulation of oxygen masks.

“As part of our pandemic response efforts at AHN, we continue to explore innovative ways to enhance the safety of our practitioners who are caring for patients with COVID-19. In addition to the personal protective equipment worn by our clinicians, this new device has the potential to further minimize exposure to pathogenic airborne particles and provide an additional layer of protection. We are excited to partner with the team at Magee Plastics on the design of the unit, and are extremely grateful to the Richard King Mellon Foundation for its support in helping bring this project to fruition,” said JP Lawrence, MD, Chair, AHN Anesthesiology Institute.

Magee Plastics, a premier provider of quality engineered products for the airline, rail, medical and other industries, will produce a total of 350 protective barrier enclosures – 200 of which will be distributed to AHN facilities and 150 to other regional health care facilities over the next several weeks.

Protective barrier enclosures have been approved by the FDA for emergency use following the Secretary of the Department of Health and Human Services’ declaration in early March that the shortage of medical equipment due to the COVID-19 pandemic warranted authorization for emergency use of alternative medical devices and products.

Similar to the experience of many organizations and companies across the U.S., the COVID-19 pandemic has significantly altered daily operations at Magee Plastics. Magee president Charles Story said the company’s commitment to the community and its employees made the decision to repurpose their operations to meet a critical need of our health care providers an easy one.

“Our region’s health care workers have answered the call of this pandemic without hesitation and in heroic fashion.  We are delighted to be able to support them through this unique collaboration, which has also enabled us to keep many of our employees working during this unprecedented time,” said Mr. Story.

“The Foundation supported this project because it advances two of our key priorities in this pandemic – protecting our frontline healthcare workers, and protecting jobs,” said Sam Reiman, Director, Richard King Mellon Foundation.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version